BIOTEC TO START FOOT ULCER STUDY

Biotec Pharmacon has entered into an agreement with Nottingham City Hospital in the UK to perform a clinical Phase II study the efficacy of soluble beta-1,3/1,6-glucan (SBG) in chronic foot ulcers in diabetes. A total of 104 patients will be included in the study.

SBG acts on immune cells in the skin to advance healing of wounds and ulcers. Diabetic patients often suffer from complicated ulcers due to dysfunctional immune cells in the skin. SBG binds to and activates immune cells in such a way that new tissue develops.